Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABA A receptor occupancy (∼10%). Since it was not clear whether this sedation was mediated via the α2/α3 or α1 GABA A subtype(s), we characterized the properties of TPA023B, a high-affinity imidazotriazine which, like MRK-409, has partial agonist efficacy at the α2 and α3 subtype but is an antagonist at the α1 subtype, at which MRK-409 has weak partial agonism. TPA023B gave dose- and time-dependent occupancy of rat brain GABA A receptors as measured using an in vivo [3 H]flumazenil binding assay, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL, the latter of which was similar to that observed in mice (25 ng/mL) and comparable to values obtained in baboon and man using [11 C]flumazenil PET (10 and 5.8 ng/mL, respectively). TPA023B was anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle, conditioned suppression of drinking, conditioned emotional response) yet had no significant effects in rodent or primate assays of ataxia and/or myorelaxation (rotarod, chain-pulling, lever pressing), up to doses (10 mg/kg) corresponding to occupancy of greater than 99%. In man, TPA023B was well tolerated at a dose (1.5 mg) that produced occupancy of >50%, suggesting that the sedation previously seen with MRK-409 is due to the partial agonist efficacy of that compound at the α1 subtype, and highlighting the importance of antagonist efficacy at this particular GABA A receptor population for avoiding sedation in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Self-citationA new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“…a subunits have distinct neuroanatomical distributions (Pirker et al., 2000), it has been proposed that particular subtypes of the GABAA receptor are responsible for specific physiological functions as well as distinct components of benzodiazepine pharmacology (Möhler, 2007;Möhler et al., 2002).”
BackgroundReversal of pathological pain through specific spinal GABAA receptor subtypes
Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008) · Nature · doi:10.1038/nature06493 · Cited by 438 · cited 1×
“…anxiolytic efficacy; de Haas et al., 2007) should encourage the pursuit of such novel compounds not only as potential non-sedating anxiolytics (Mirza et al., 2008) but also for other indications such as schizophrenia (Lewis et al., 2008) and pain (Knabl et al., 2008; Munro et al., 2008, 2009).”
BackgroundAnalysis of the set of GABAA receptor genes in the human genome
Simon, J., Wakimoto, H., Fujita, N., Lalande, M., & Barnard, E. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401354200 · Cited by 253 · cited 2×
“Finally, the efficacy of TPA023B was measured at human recombinant GABAA receptors expressed in the same cell lines as described above using a 36Cl flux assay (Smith et al., 2001).”
MethodDias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247
Self-citationde Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84
Self-citationAtor, N. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900009883 · Cited by 59
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52 · cited 3×
“%) receptor occupancy, whereas MRK-409 (also known as MK-0343) produced sedating effects at relatively low levels of occupancy (Atack, 2009; de Haas et al., 2007, 2008).”
BackgroundSelf-citation
Cited by
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Cheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
“54 However, the question of whether other subunits were involved in sedation was quickly overthrown as the clinical results of TPA023B, published shortly after, as an α 1 sub-type antagonist and α 2 / α 3 subtype partial agonist, produced a sedation-free anxiety suppressing profile, 50…”
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Metadata
- Authors
- Atack, Jr., Hallett, D., Tye, S., Wafford, K., Ryan, C., Sanabria-Bohórquez, S., Eng, W.-S., Gibson, R., Burns, H., Dawson, G., Carling, R., Street, L., Pike, A., De Lepeleire, I., Van Laere, K., Bormans, G., de Hoon, J., Van Hecken, A., McKernan, R., Murphy, M., & Hargreaves, R.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2010-02-15
- Volume
- 25
- Issue
- 3
- Pages
- 329-344
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2064596734
- Cited by
- 63
- References
- 11
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist. https://app.cochat.ai/papers/10.1177/0269881109354928
- The paper
- Atack, Jr., Hallett, D., Tye, S., Wafford, K., Ryan, C., Sanabria-Bohórquez, S., Eng, W.-S., Gibson, R., Burns, H., Dawson, G., Carling, R., Street, L., Pike, A., De Lepeleire, I., Van Laere, K., Bormans, G., de Hoon, J., Van Hecken, A., McKernan, R., . . . Hargreaves, R. (2011). Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist. Journal of Psychopharmacology. https://doi.org/10.1177/0269881109354928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.